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Invasive fungal disease (IFD) is one of the most serious complications of therapy in patients with immune suppression. It particularly 
concerns patients treated for malignant hematological diseases, immune deficiencies, or undergoing hematopoietic cell transplantation 
(HCT). Development of IFD can abrogate the effect of previous therapy and contributes to dismal outcome of the underlying disease. 
The Working Group consisting of members of the Polish Society of Hematology and Blood Transfusion, the Polish Society of Pediatric 
Oncology and Hematology, and the Polish Adult Leukemia Study Group has prepared recommendations for the diagnostic and 
therapeutic management of IFD in adults and children. This paper presents the current recommendations for patients in immune 
suppression treated in Polish pediatric and adult hematology and HCT centers, based on the guidelines of the European Conference 
on Infections in Leukaemia (ECIL) 2015–2019. Levels of diagnosis of IFD (possible, probable, and proven) and antifungal management 
(prophylaxis, as well as empirical and targeted therapies) are declared according to updated international criteria of the European 
Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) 2019. Patients with primary diagnosis 
of acute lymphoblastic leukemia, acute myeloblastic leukemia, severe aplastic anemia, chronic granulomatous disease, and severe 
combined immunodeficiency, as well as patients after allogeneic HCT, are included in the high-risk groups for development of IFD. 
For these patients, antifungal prophylaxis based on azoles or micafungin is recommended. In empirical therapy, caspofungin or 
liposomal/lipid formulas of amphotericin B are recommended. The Working Group has discouraged the use of itraconazole in capsules 
and amphotericin deoxycholate. Detailed guidelines for first- and second-line targeted therapies for invasive candidiasis, aspergillosis, 
mucormycosis, fusariosis, and scedosporiosis, as well as the principles of the recommended dosing of antifungals, are presented in this 
paper.
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Introduction
Invasive fungal disease (IFD) is one of the most serious complications 
during and after hematopoietic stem cell transplantation (HCT), in 
anticancer therapy – especially in hematology, as well as in patients 
with other severe immune suppression states, such as severe aplastic 
anemia (SAA) or primary immunodeficiency diseases (PIDs) [1].
The epidemiology of IFD has evolved considerably over the past 
decades, in association with advances in supportive care, in particular, 
in prophylaxis and therapy of IFD. Retrospective analyses and 
prospective studies indicate that patients at the highest risk for the 
development of IFD are those undergoing intensive chemotherapy 
for acute myeloid leukemia (AML) and those treated with allogeneic 
hematopoietic stem cell transplantation (allo-HCT) [2, 3]. Recent data, 
however, confirm an equally high risk of IFD among selected patients 
with lymphomas and acute lymphoblastic leukemia (ALL).
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The current incidence of IFD in Poland is 21.2% in children after HCT, 
8.8% in children undergoing anticancer treatment [4, 5, 6], and 6.3% 
in adults after HCT [3]. However, the incidence of IFD is even higher 
in some subpopulations: 28.3% and 14.0%, respectively, in children 
and adults undergoing allo-HCT; 29.4% and 11.3%, respectively, in 
children and adults with ALL; and 41.2% and 13.2%, respectively, in 
children and adults with AML [3]. Introduction of the national program 
of antifungal prophylaxis with reimbursement of posaconazole and 
voriconazole in selected high-risk groups of patients in 2014–2015 
has resulted in a decrease of IFD incidence, confirmed in pediatric 
patients [4].
The most common IFD in patients treated intensively is invasive 
aspergillosis (IA), usually caused by Aspergillus fumigatus. A large 
retrospective Italian analysis, covering >11,000 patients treated with 
hematologic malignancies, showed an occurrence of IA at the level 
of 2.6%, but among AML patients, this percentage was as high as 
12% [7]. In allo-HCT recipients, IA is diagnosed with a frequency of 
5.8%–10% depending on the type of transplantation and the intensity 
of the immunosuppressive procedure. In >90% of IA cases, pulmonary 
disease is found [invasive pulmonary aspergillosis (IPA)], but 
aspergillosis with involvement of the paranasal sinuses and the central 
nervous system (CNS) is also observed, as are the disseminated 
forms. IA-related mortality in patients treated conventionally and after 
allo-HCT reaches 27% and 40%, respectively, and is lower than in 
the previous decade [7].
An important problem noted in recent years is the increase in the 
incidence of IFD caused by mold fungi other than Aspergillus, 
in particular, Mucorales, Fusarium spp., and Scedosporium spp. 
Mucormycosis currently accounts for about 7% of invasive fungal 
infections, is characterized by high mortality (>60%), and often 
coexists with aspergillosis [2, 8, 9]. Mucormycosis is more common 
among the elderly and in patients with concomitant diseases, such 
as diabetes, renal failure, and malnutrition, and is usually difficult 
to diagnose. In its clinical course, involvement of the CNS, nasal 
sinuses, and lungs is observed, and disseminated forms are also 
observed.
Over the past 20 years, a significant improvement in the diagnostics 
and classification of IFD [1], in addition to development of antifungal 
drugs, has been achieved. Nevertheless, IFD remains one of the 
most frequent infections in these patient populations. The joint group 
of members of Polish hematology scientific societies aims to provide 
clinicians with best guidance in their everyday working practice. The 
objective of this paper is to provide comprehensive Polish guidelines 
focusing on the life-threatening IFDs.
Methods
The Working Group was created by members of the Polish Society 
of Hematology and Blood Transfusion, the Polish Society of Pediatric 
Oncology and Hematology, and the  Polish Adult Leukemia Study 
Group with the task to prepare guidelines for the management 
of patients treated in the departments of hematology, HCT, and 
pediatric hematology and oncology. Recommendations for adults 
treated in hematology and/or HCT centers, as well as for children 
treated in oncology/hematology and/or HCT centers, were prepared 
based on previous Polish guidelines [10], current recommendations 
from the ECIL [11, 12, 13], the Infectious Diseases Society of America 
(IDSA) [14–17], and the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) [18], supplemented by ECIL-8 
guidelines (www.ecil-leukaemia.com) and literature from the past 
5 years. Specificity of the Polish health-care system was taken 
into account. The recommendations were graded according to the 
modified ECIL-8 grading system (Tab. I).
Risk groups
Based on international guidelines [13], previous Polish pediatric 
guidelines [10], current epidemiological Polish data [3, 4], and clinical 
experience, the Working Group stratified patients into various risk 
groups. The high-risk group for development of IFD includes the 
following diagnoses: ALL, AML, myelodysplastic syndromes (MDSs), 
SAA, chronic granulomatous disease (CGD), severe combined 
immunodeficiency (SCID), as well as patients after allo-HCT. All other 
patients are regarded as being in the low-risk group for IFD (Tab. II).
Additional risk factors for development of IFD are as follows: 
neutropenia >10 days; treatment with corticosteroids at 
a therapeutic dose of ≥0.3 mg/kg for ≥3 weeks in the past 60 days; 
immunosuppressive therapy during the past 90 days; treatment with 
recognized B-cell immunosuppressants (e.g., ibrutinib); and graft- 
-versus-host disease (GVHD) [1].
Table I. Grading system
Strength of Recommendation (SoR) Definition
Grade A Strong support of a recommendation for use
Grade B Moderate support of a recommendation for use
Grade C Marginal support of a recommendation for use
Grade D Support for a recommendation against use
Quality of Evidence (QoE) Definition
Level I Evidence from at least 1 properly designed randomized, controlled trial (oriented on the primary end point of the trial)
Level II Evidence from at least 1 well-designed clinical trial (including secondary end points), without randomization; from 
cohort or case controlled analytic studies (preferably from >1 centers; from multiple time series; or from dramatic 
results of uncontrolled experiments
Level III Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies, or reports of 
expert committees
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Definitions of invasive fungal disease
In 2002, with subsequent modifications in 2008 and 2019, the 
Infectious Diseases Group of the EORTC and the MSG presented 
the definitions and classification of invasive mycoses, distinguishing 
the diagnoses of confirmed, probable, and possible IFD, based on 
the results of diagnostic tests [1, 19, 20]. Published autopsy data 
indicate that ante-mortem diagnosis of IFD has currently reached 
50% of cases. With respect to the level of diagnosis, the current 
updated classification includes proven, probable, and possible IFD 
(Tab. III) [1].
Updated 2019 criteria for diagnosis of proven IFD include 
[1]:
Yeast infection
1.  Histopathologic, cytopathologic, or direct microscopic 
examination of a specimen obtained by needle aspiration 
or biopsy from a normally sterile site (other than mucous 
membranes) showing yeast cells, e.g., Cryptococcus spp., 
indicating encapsulated budding yeasts, or Candida spp., 
showing pseudohyphae or true hyphae.
2.  Recovery of a yeast specimen by culture of a sample obtained 
by a sterile procedure (including a freshly placed [<24 hours ago] 
drain) from a normally sterile site showing a clinical or radiological 
abnormality consistent with an infectious disease process.
3.  Blood culture that yields yeast (e.g., Cryptococcus or Candida 
spp.) or yeast-like fungi (e.g., Trichosporon spp.).
4.  Amplification of fungal DNA by polymerase chain reaction (PCR), 
combined with DNA sequencing, when yeasts are seen in 
formalin-fixed paraffin-embedded tissue.
5.  Cryptococcal antigen in cerebrospinal fluid (CSF) or blood 
confirms cryptococcosis.
Mold infection
1.  Histopathologic, cytopathologic, or direct microscopic 
examination of a specimen obtained by needle aspiration or 
biopsy, in which hyphae or melanized yeast-like forms are seen, 
accompanied by evidence of associated tissue damage.
2.  Recovery of a hyaline or pigmented mold by culture of 
a specimen obtained by a sterile procedure from a normally 
sterile and clinically/radiologically abnormal site consistent 
with an infectious disease process, excluding bronchoalveolar 
lavage (BAL) fluid, a paranasal or mastoid sinus cavity 
specimen, and urine.
3.  Blood culture that yields a mold (e.g., Fusarium spp.) in the 
context of a compatible infectious disease process.
4.  Amplification of fungal DNA by PCR, combined with DNA 
sequencing, when molds are seen in formalin-fixed paraffin- 
-embedded tissue.
Diagnostics
The diagnosis of fungal infection should be based on the entire 
picture, taking into account risk factors, clinical symptoms, and 
results of radiological and microbiological tests. The most common 
signs of IFD are fever, which persists for more than 5–7 days despite 
the use of broad-spectrum antibiotic therapy, and clinical symptoms 
of respiratory infection. In any case of suspected IFD, the presence 
of the fungus should be demonstrated by direct microscopic 
assessment and/or culture and/or histopathological examination, 
which is a direct evidence of invasive mycosis but often requires the 
use of invasive procedures such as BAL or biopsy of the affected 
tissue. However, the BAL result does not differentiate fungal invasion 
from colonization.
Imaging
High-resolution computed tomography (HRCT) enables early diagnosis 
of IPA and has prognostic significance. The most characteristic 
feature of angio-IPA is the “halo” sign in HRCT; atypical infiltrative 
nodular lesions are often observed and are difficult to interpret, and 
the image with the “air crescent” is a late radiological symptom. The 
radiological picture of IFD of the paranasal sinuses and the CNS in 
both CT and magnetic resonance imaging (MRI) is not characteristic. 
Pulmonary abnormalities such as tree-in-bud opacities and interstitial 
abnormalities are excluded from the clinical features as they can be 
due to a wide range of pathologies in addition to IFD [1].
Table II. Risk groups for development of invasive fungal disease
High risk ALL, AML, SAA, MDS, CGD, SCID, allo-HCT
Low risk Auto-HCT, patients with other malignancies undergoing chemotherapy 
Table III. Definitions of invasive fungal disease
Level of diagnosis Definition
Proven Histopathologic, cytopathologic, or direct microscopic examination or positive culture of a specimen obtained by needle aspiration or biop-
sy, including blood sample. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised
Probable Probable invasive fungal disease requires the presence of at least 1 host factor, a clinical feature, and mycologic evidence (Tab. IV), and it is 
proposed for immunocompromised patients only
Possible Cases that meet the criteria for a host factor and a clinical feature but for which mycological evidence has not been found are considered 
possible IFD. (1,3)-β-D-glucan (BDG) is not considered to provide mycological evidence of any invasive mold disease. The possible category 
is proposed for immunocompromised patients only, except for endemic mycoses
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Imaging: pediatric distinctness
Radiographic findings are less specific in children than those reported 
in adults. Chest CT scans in children with proven IPA commonly show 
nonspecific changes and not the halo sign, air crescent formation, or 
cavitation seen in adults [1].
Galactomannan (GM) assay
Among the serological tests, the GM assay is validated for the 
diagnosis of IA. For high-risk neutropenic patients, it is recommended 
that serum GM should be determined twice a week, with a positive test 
result ≥ 0.5 in two consecutive tests. This marker can also serve as 
an indicator of response to antifungal therapy. The GM examination 
in BAL is useful in the pulmonary diagnostics of IA in patients with 
and without neutropenia. Index GM > 1.0 in BAL is regarded as 
positive, while in the CSF, GM ≥ 0.7 in single or ≥ 0.5 in two tests is 
considered positive. In patients treated with antimold antifungals, the 
GM index can be false negative; in this cohort, negative GM does not 
exclude the possibility of IFD.
Mannan determination
The clinical value of mannan test results is currently regarded as 
low due to difficulties in interpretation. Currently, it is not regarded 
as distinctive [1].
β-D glucan (BDG) determination
BDG is a component of the cell wall of yeast and mold fungi. The 
presence of BDG in serum confirms IFD but does not differentiate 
among aspergillosis, candidiasis, and fusariosis. False-positive 
and false-negative test results limit its practical application in the 
diagnosis of mold fungi. Currently, BDG is not considered to provide 
mycological evidence of any invasive mold disease [1].
PCR analysis
Progress in standardization has increased the value of PCR, which 
is now recommended with the use of international standardization. 
Systematic reviews of Aspergillus PCR methods for blood and BAL 
fluid conclude that PCR provides a robust diagnostic test for screening 
and confirming the diagnosis of Aspergillus infection [1, 18].
Biomarkers: pediatric distinctness
There are also far fewer data to support the clinical use of non-
culture-based fungal biomarkers in children, although the GM assay 
performs similarly in children and adults when used as an adjunctive 
tool to diagnose IA. Likewise, there are few data regarding the 
use of BDG, Candida mannan antigen, and anti-mannan antibody 
biomarkers in pediatrics. Recent data support the utility of BDG in 
the CSF for the diagnosis and therapeutic monitoring of children with 
Candida meningoencephalitis, but data regarding the utility of PCR 
assays and the T2Candida assay for diagnosis are sparse [1].
Diagnostics of IFD should be focused on the presence of clinical 
(imaging) and microbiological (culture, biomarkers) evidences in 
patients with risk factors and symptoms and signs of infection (Tab. IV).
Therapy
The strategy of prophylaxis and antifungal treatment was developed as 
part of the ECIL as a result of cooperation of experts from the European 
Society for Blood and Marrow Transplantation (EBMT), EORTC, 
European LeukemiaNet, and the International Immunocompromised 
Host Society (ICHS). The principles of antifungal prophylaxis, 
empirical therapy, and preemptive therapy; treatment of confirmed 
mycoses based on ECIL guidelines and the IDSA recommendation 




Antifungal prophylaxis in adults with acute leukemias
Patients with AML treated with intensive chemotherapy should 
receive posaconazole in prophylaxis of IFD (Tab. V). The drug 
is effective in reducing the rate of IA and influences the survival 
(Grade AI). Posaconazole should be given as oral suspension (po) 
Table IV. Clinical and microbiological evidences of IFD
Clinical evidences Suggestive imaging: pulmonary HRCT, CT/MRI of sinuses, abdominal CT/MRI, CNS MRI
and/or neutropenic fever not resolving or recurrent in spite of use of broad-spectrum antibiotics for at least 72 hours
and/or signs and symptoms of septic shock in neutropenic patient
Microbiological evidences Biomarkers (GM, rarely cryptococcal antigen)
and/or PCR for fungi: positive
and/or histopathologic examination for fungi: positive
and/or blood culture and/or culture of biologic specimen from normally sterile site: positive for fungi



































TDM –  therapeutic drug monitoring;  LAmB – liposomal amphotericin-B;  ABLC – amphotericin B lipid complex
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(3 × 200 mg) or intravenously (iv) (2 × 300 mg on the first day, followed 
by 1 × 300 mg daily) until neutropenia recovery. In the ALL setting, 
prophylaxis with fluconazole (400 mg/day, iv/po) or micafungin 
(50 mg/day, iv) is advisable.
Antifungal prophylaxis in adults after HCT
For lower-risk HCT recipients (HCT from matched sibling donor, low 
incidence of mold IFD in the center) during neutropenia, fluconazole 
is recommended for antifungal prophylaxis with monitoring of GM and 
possibly HRCT (Grade AI). Micafungin (50 mg/day, iv), with a broader 
spectrum of antifungal activity than fluconazole, is also effective 
(Grade BI). Itraconazole – available in Poland only in the form of 
capsules – is not recommended for prophylactic use, as opposed to 
the oral solution or intravenous form.
In higher-risk HCT patients (HCT from mismatched/unrelated donor, 
high rate of mold IFD in the center), use of voriconazole 2 × 200 mg 
po (2 × 400 mg on the first day) may be considered (Grade BI). Due 
to drug interactions, second-generation azoles should not be used 
during high-dose chemotherapy.
After hematopoietic reconstitution, in patients treated for GVHD, 
posaconazole (Grade AI) is the most effective in preventing IA. 
Secondary antifungal prophylaxis involves the prevention of IFD 
reactivation in patients undergoing allo-HCT.
Children
Antifungal prophylaxis in children with high risk for IFD 
development
Effective antimold prophylaxis should be used in patients with risk for 
IFD development (Grade BII, Tab. II). The therapy of choice in Poland 
remains posaconazole oral suspension (Grade BI). Its twice-daily 
body-weight-based dosing algorithm has been proposed by Welzen 
et al. [21] (Tab. VI) [21]. Alternatively, for pediatric patients, from 
1 month to 12 years of age, a starting dose of posaconazole 6 mg/kg 
three times daily may be used [22]. Parallel administration of proton-
pump inhibitors (PPIs) (omeprazole) and/or Vinca alkaloids should 
be avoided during posaconazole prophylaxis. Temporary withdrawal 
of azole prophylaxis is obligatory when a patient is given Vinca 
alkaloids (data from US clinical trials suggest a minimum of 24 hours 
of withdrawal before and after administration of Vinca alkaloids, but 
this has not been confirmed, yet). Micafungin in the dose 1 mg/kg/
day might be an alternative for posaconazole (liver function should 
be monitored). Fluconazole prophylaxis (dose: 8–12 mg/kg/day) may 
be considered (Grade CI), but one should remember that this azole 
is effective mainly against Candida albicans (Tab. VII). To consider 
fluconazole prophylaxis, children have to fulfill two conditions: 
(1) they cannot be colonized by non-albicans Candida species (i.e., 
C. glabrata, C. krusei); (2) GM has to be monitored twice weekly due 
to the inefficiency of fluconazole against molds.
Antifungal prophylaxis in children undergoing allo-HCT: 
neutropenic phase (preengraftment)
Primary antifungal prophylaxis is recommended in children 
undergoing allo-HCT in neutropenic phase until engraftment 
(Grade BII). Therapeutic options include fluconazole (effective only 
against selected yeasts), micafungin, posaconazole, or voriconazole. 
Voriconazole dosing is presented in table VIII (according to 
the summary of product characteristics (SPC)). Due to several 
drug–drug interactions, azoles (except for fluconazole) should not be 
used during high-dose chemotherapy.
Antifungal prophylaxis in children undergoing allo-HCT: 
post-engraftment phase
In the absence of GVHD, antifungal prophylaxis should be continued 
after engraftment until immune recovery. In the presence of GVHD 
treated with augmented immunosuppressive therapy, prophylaxis 
against mold and yeast infections is recommended (Grade AII). The 
available options are posaconazole (Grade BI) and voriconazole 
(Grade BI).
Table VI. Posaconazole dosing algorithm for children








Table VII. Recommendations for antifungal prophylaxis in children
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Antifungal prophylaxis in children undergoing auto-HCT
Fluconazole as primary prophylaxis against Candida albicans should 
be considered. Micafungin or caspofungin may be considered in 
patients with C. glabrata/C. krusei colonization.
Antifungal prophylaxis in children with low risk for IFD 
development (Tab. I)
Antifungal prophylaxis is recommended in selected patients with 
additional risk factors.
Secondary antifungal prophylaxis in children
Secondary antifungal chemoprophylaxis is recommended, targeted 
against the previous fungal pathogen, for as long as the patient is 
neutropenic or immunosuppressed (Grade AII). Either posaconazole 
or voriconazole may be considered.
Empirical antifungal therapy
IFD is often the cause of morbidity and mortality among high-risk 
febrile neutropenic patients. Although the diagnostic procedures 
have improved, accurate diagnosis of IFD remains difficult and is 
often delayed. Empirical antifungal therapy applies to patients in 
neutropenia with isolated fever that lasts more than 3–4 days despite 
broad-spectrum antibiotic therapy and is widely used in practice in 
hematologic and transplant centers, despite the lack of evidence in 
randomized trials for its effectiveness.
Empirical antifungal therapy must be considered in high-risk 
neutropenic patients who have persistent (or recurrent) fever after 
72 hours of broad-spectrum antibiotic therapy and no identified 
infection source (Grade BII) [11, 18, 23, 24].
The choice of agent for empiric antifungal therapy depends 
mostly on previous antifungal prophylaxis. In patients receiving 
fluconazole prophylaxis, mold infections or fluconazole-resistant 
Candida spp. are the most likely causes; therefore, liposomal/
lipid formulations of amphotericin B, echinocandins (Grade AI) or 
voriconazole (Grade BI) are indicated (Tab. IX). In patients who have 
been receiving posaconazole or voriconazole prophylaxis, the drugs 
of choice are liposomal/lipid formulations of amphotericin B (Grade 
AI) [25–28]. For patients who have not been receiving antifungal 
prophylaxis, Candida spp. are the most likely cause of invasive 
fungal infection, and the best option of empiric therapy comprises 
the echinocandins (caspofungin, micafungin) (Grade AI) [25–28]. 
Additionally, echinocandins are preferred in patients who have no 
obvious sites of infections, while voriconazole or amphotericin B 
preparations are preferred in patients with pulmonary infiltrates that 
are caused most probably by mold infection (Tab. X).
In empirical treatment, liposomal amphotericin (3 mg/kg, iv), 
caspofungin (70 mg, iv, on the first day, then 50 mg, iv) or micafungin 
(100 mg/day, iv) (Grade AI) have the highest recommendations. 
Table VIII. Voriconazole dosing
Intravenous formulation Loading dose Maintenance dose
Adults 2 × 6 mg/kg on first day 2 × 4 mg/kg
Children 2–12 years and 12–14 years old with bw < 50 kg 2 × 9 mg/kg on first day 2 × 8 mg/kg
Children 12–14 years old with bw >50 kg and children 14–18 years As in adults As in adults
Oral formulation Loading dose (should be given intravenously) Maintenance dose
Adults with bw ≥40 kg 2 × 400 mg, iv, on first day 2 × 200 mg
Adults with bw <40 kg 2 × 200 mg, iv, on first day 2 × 100 mg
Children 2–12 years and 12–14 years old with bw < 50 kg 2 × 9 mg/kg, iv, on first day 2 × 9 mg/kg (max. 2 × 350 mg)
Children 12–14 years old with bw >50 kg and children 14–18 years As in adults As in adults
bw – body weight
Table IX. Summarized recommendations for empirical antifungal therapy
Antifungal Adults Children Comments
Caspofungin AI AI Not active against Mucorales 
LAmB AI AI
ABLC BI BI Infusion-related toxicity
Voriconazole BI Not active against Mucorales and selected Candida
Micafungin AI
Itraconazole DI Not active against Mucorales and selected Candida
Fluconazole CI Not active against Aspergillus and selected Candida
D-AmB DII DII
Combination therapy DIII DIII
LAmB – liposomal amphotericin-B; ABLC – amphotericin B lipid complex;  D-AmB – amphotericin B deoxycholate 
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Lipid amphotericin (5 mg/kg, iv) (Grade BI) is also acceptable, 
while amphotericin deoxycholate (D-AmB; 0.5–1 mg/kg/day, iv) is 
contraindicated due to toxicity (Grade DII).
Taking into account the increasing prevalence of mucormycosis, it is 
important to remember that echinocandins and voriconazole have no 
activity against molds. If mucormycosis is suspected, a liposomal/lipid 
amphotericin B formulation or isavuconazole should be given [12].
Regarding the toxicity of antifungal drugs, both caspofungin and 
voriconazole induce nephrotoxicity and severe infusion-related events 
significantly less often as compared to amphotericin B formulations, 
whereas patients receiving voriconazole have more episodes of 
transient visual changes and hallucinations. Among the mentioned 
antifungal drugs, echinocandins have the best toxicity profile and show 
lower potential to interact with other drugs [28, 29, 30].
Empirical antifungal therapy in children
Empirical antifungal therapy, when selected as a strategy, should 
be started after 72 hours of fever and continued until resolution 
of neutropenia. Empirical therapy can be considered in children 
with acute leukemia, after HCT, with GVHD, or undergoing 
immunosuppressive treatment from any other cause. Antifungals 
recommended for empirical therapy in children are caspofungin, 
LAmB, ABLC, or voriconazole. Switch in antifungal class is necessary 
in case of previous antifungal prophylaxis. If fluconazole was used in 
prophylaxis, then echinocandins, LAmB, or voriconazole can be used 
in empirical therapy. When voriconazole or posaconazole was used 
in prophylaxis, then LAmB is the drug of choice in empirical therapy.
Preemptive antifungal therapy
The alternative to empirical treatment strategy is diagnostic test-
guided preemptive antifungal therapy. Preemptive therapy involves 
initiating antifungal therapy based upon the results of serial screening 
with GM, BDG, PCR assays, or pulmonary CT/HRCT scan [11, 18]. 
In most cases, it is defined by positive GM/PCR testing. It has been 
proved that in the preemptive strategy, the frequency of antifungal 
use and duration of therapy are significantly decreased as compared 
to the empirical strategy. The preemptive approach can result in more 
documented cases of IFD without compromise on survival and can 
be used as an alternative to empiric antifungal therapy, both in adults 
(Grade BII) and children (Grade BII) [18, 31]. It should be underlined 
that simultaneously with empiric or preemptive antifungal therapy, the 
greatest effort should be made to establish a proper diagnosis.
Therapy of invasive candidiasis
The most frequent species among yeasts is Candida albicans. 
However, an increase of infections caused by C. parapsilosis, 
C. tropicalis, C. glabrata, and – recently – C. auris is being 
observed, which is probably caused by wide prophylaxis with azoles. 
C. krusei is inherently resistant to fluconazole, and C. glabrata has 
variable susceptibility to fluconazole; thus, this compound is not 
recommended in these cases. The first-line antifungals in invasive 
candidiasis are caspofungin, micafungin, anidulafungin, and 
LAmB/ABLC, for C. albicans, C. glabrata, and C. krusei (Tab. XI). 
Voriconazole is also recommended against C. krusei species. 
Infections with C. parapsilosis should be treated with fluconazole or 
LAmB/ABLC. There are no clinical practice guidelines available for 
the management of C. auris in transplant patients, although empirical 
treatment with an echinocandin would be appropriate considering the 
reported susceptibility patterns [32].
A switch in class should be considered in patients with breakthrough 
infections on antifungal prophylaxis or empirical therapy (no grading) 
[13]. When the Candida species is azole-susceptible, step-down 
to fluconazole can be considered in stable patients after 5 days 
of iv therapy. In patients with C. krusei infection, switching to oral 
voriconazole is an option [12].
Table X. Empirical antifungal therapy in specific clinical situations
   Clinical situation Recommended Not recommended
Previous azoles LAmB, echinocandins Azoles
Shock LAmB, echinocandins Azoles
Severe renal failure Echinocandins, voriconazole (oral formula) LAmB, fluconazole
Hepatic failure Echinocandins, LAmB (weak recommendation) Azoles
Table XI. Summarized recommendations for the management of candidiasis
Antifungal Candida spp. (without identification) C. albicans C. glabrata C. krusei C. parapsilosis
Caspofungin AII AII AII AIII BIII
Micafungin AII AII AII AIII BIII
Anidulafungin AII AII AIII AIII BIII
Voriconazole BII CIII CIII
Fluconazole CIII CIII AIII
LAmB AII BII BII BII BII
ABLC BI BII BII BII BII
D-AmB CII CII CII CII CII
LAmB – liposomal amphotericin-B; ABLC – amphotericin B lipid complex;  D-AmB – amphotericin B deoxycholate 
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Combination antifungal chemotherapy (e.g., amphotericin B plus 
flucytosine and other combinations) might be considered in special 
situations (e.g., severe life-threatening infection; compromised drug 
penetration in CNS infection; and complicated bone and joint, urinary 
tract, and intra-abdominal infections; no grading) [13].
Catheter removal
Most recent studies suggest a beneficial effect of catheter removal 
on outcome. Early adequate therapy and removal of central venous 
line were independently associated with lower mortality [1, 33, 34]. 
The recommendation is to rapidly remove the catheter (Grade BII) 
irrespective of the Candida species. If the central venous catheter 
cannot be removed, treatment should include an echinocandin or 
a liposomal/lipid formulation of amphotericin B due to their better 
activity on Candida biofilms [12].
Duration of antifungal therapy in candidiasis
The optimal duration of therapy for uncomplicated candidemia 
is 14 days after blood cultures are sterile; resolution of signs and 
symptoms; and resolution of neutropenia. For tissue-invasive 
candidiasis, the duration of treatment is defined by the site, the 
patient’s response, and resolution of predisposing disorders [13].
Therapy of invasive aspergillosis
Adults
Voriconazole and isavuconazole are currently recommended for the 
treatment of confirmed aspergillosis in first-line therapy (Tab. XII). 
Based on randomized studies, voriconazole has been shown to 
reduce mortality in IA compared to conventional amphotericin. 
Treatment should be started with an iv dose of 2 × 6 mg/kg on 
the first day, then 2 × 4 mg/kg. Monitoring of blood drug levels is 
recommended because of the variable nonlinear pharmacokinetics 
of voriconazole. The neurotoxic, hepatic, and ocular complications 
occurring during voriconazole therapy are reversible, but their 
occurrence requires discontinuation of the drug. Late complications 
relate to the risk of developing skin cancer. In 2016, the results of 
a prospective study confirmed the similar efficacy of isavuconazole 
and voriconazole in the treatment of IA [11]. Isavuconazole available 
in iv and oral forms is better tolerated than voriconazole [35]. Both 
liposomal and lipid amphotericin are effective in the treatment of IA, 
and their use should be considered in the case of azole resistance 
and intolerance, as well as in patients receiving second-generation 
azole prophylaxis (posaconazole, voriconazole). For the treatment 
of IA, D-AmB should not be used. Currently, D-AmB is considered to 
have no role in the treatment of IA when more-effective and less-toxic 
agents are available. Its limited efficacy and its poor safety profile led 
to a recommendation against its use [12].
Caspofungin, as monotherapy or in combination with voriconazole or 
amphotericin, or amphotericin monotherapy is proposed for second-
line IA therapy. In some patients, there are indications for surgical 
intervention.
Surgical treatment
Surgical treatment is recommended in the cases of lesion contiguous 
to a large vessel, hemoptysis from a single lesion (embolization is 
an alternative), and localized extrapulmonary lesion, including CNS 
lesion. Additionally, decreasing the mass of fungal burden might be 
considered.
Duration of antifungal therapy in aspergillosis
It is not possible to define the time necessary for successful treatment 
of IA/IPA, and the range is 3–50 weeks. According to IDSA and 
ESCMID, it should be no shorter than 6–12 weeks [14, 15, 18]. It should 
be continued during immunosuppressive treatment until resolution of 
signs and symptoms. Patients after IA/IPA therapy should be given 
secondary prophylaxis when undergoing subsequent chemotherapy 
or any other immunosuppressive therapy. The European survey of 
the Infectious Diseases Working Groups of EBMT, ESCMID, EORTC, 
and Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie 
Maligne (SEIFEM) has shown that there is large variability between 
centers; however 6 and 12 weeks of treatment are the most often used 
lengths of therapy (Lanternier et al., submitted).
Table XII. Summarized recommendations for the management of aspergillosis in immunocompromised patients
Intervention Adults Children Comments
First-line treatment
Voriconazole AI AI
Liposomal amphotericin B AI BI




LAmB + Voriconazole CII CII
LAmB + Caspofungin CII CII
LAmB – liposomal amphotericin-B; ABLC – amphotericin B lipid complex;  D-AmB – amphotericin B deoxycholate
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Children
Voriconazole is the drug of choice in the treatment of possible, 
probable, and proven pediatric IA (Grade AI, Tab. XII). The loading 
dose and the first-week therapy should be via the iv route, and the 
use of oral formulations may be considered only in patients with 
documented clinical improvement. Voriconazole remains the current 
treatment of choice for infections involving the CNS. A switch in 
class is to be considered in patients with breakthrough aspergillosis 
on mold-active azole prophylaxis. Liposomal (Grade BI) or lipid 
(Grade BII) formulations of amphotericin B remain the first option if 
azole resistance is suspected or confirmed. Options for second-line 
treatment include LAmB in amphotericin-B-naive patients (Grade BI) 
and voriconazole in voriconazole-naive patients (Grade AI). Further 
options approved in children include caspofungin (Grade AII) and 
ABLC (Grade BII). One may consider combination therapy in the 
most severe cases. Either voriconazole or an amphotericin B product- 
-plus-an echinocandin might be used for salvage treatment 
(Grade CII). Isavuconazole is a promising agent, which has proved its 
high efficacy in adults. The results of an ongoing Phase II trial on the use 
of isavuconazole in pediatric patients with aspergillosis are pending. 
Therefore, the pediatric recommendations for targeted aspergillosis 
therapy with isavuconazole have not yet achieved grading.
Therapy of invasive mucormycosis
Treatment of mucormycosis is comprehensive and should include 
treatment of the underlying disease, antifungal pharmacotherapy, 
and surgery. The importance of correcting diabetes and acidosis, 
treatment of granulocytopenia, reducing doses, or discontinuing 
steroids and/or other immunosuppressants is emphasized. As the 
first line, liposomal amphotericin in high doses (5–10 mg/kg) or, 
in cases without CNS involvement, lipid amphotericin (5 mg/kg) is 
recommended. Posaconazole or isavuconazole can be used as 
rescue therapy (Tab. XIII).
Surgical treatment
Surgical treatment is recommended whenever possible, particularly 
in rhino-orbito-cerebral, soft tissue, or localized pulmonary lesion 
involvement, and in disseminated presentation [36, 37].
Children
Surgical treatment is mandatory, if possible. Control of primary 
disease and comorbidities (e.g., diabetes) is essential. Drug of choice 
is LAmB or ABLC in high doses (LAmB 10 mg/kg; ABLC 7.5 mg/kg).
Duration of antifungal therapy in mucormycosis
Long-term treatment is necessary. Median duration of antifungal 
treatment in recent studies was 102 days, ranging from 27 days up 
to 735 days [38, 39].
Therapy of fusariosis
The taxonomic revision defined species complexes with similar 
physiological and molecular features within the genus Fusarium. 
Some of these plant pathogens cause opportunistic infections in 
humans: Fusarium solani species complex (FSSC), F. oxysporum 
species complex (FOSC), and F. fujikuroi species complex 
(FFSC) [40]. Fusarium keratitis and onychomycosis are the main 
manifestations in immunocompetent individuals, while involvement of 
other organs and disseminated disease are observed in neutropenic 
and immunosuppressed patients [40, 41].
Fusarium spp. possess intrinsic resistance to most antifungal 
agents with variable susceptibility to amphotericin B and extended-
spectrum triazoles [40, 41, 42]. Based on available data, the 
European Fungal Infection Study Group (EFISG), the ESCMID, 
and the European Confederation of Medical Mycology (ECMM) 
recommend voriconazole (Grade AII) or liposomal/lipid formulation 
Table XIII. Summarized recommendations for the management of mucormycosis in hematology/HCT patients






LAmB + Posaconazole CIII CIII




Combination therapy BIII BIII
Adjunctive treatment
Surgical debridement and drainage AII AII Essential for favorable outcome
Reversal of immunosuppression AII AII Improves the outcome
Granulocyte transfusion CIII CIII Granulocytes as a protective factor; lack of solid data
LAmB – liposomal amphotericin-B; ABLC – amphotericin B lipid complex
69
A c t a  H a e m a t o l o g i c a  P o l o n i c a
of amphotericin B (Grade BII) for management of invasive fusariosis 
[43]. Posaconazole is advised as salvage therapy (Grade AII) 
[41, 43]. Summarized recommendations are presented in table XIV.
When possible, immune defenses should be restored by 
immunosuppression tapering and granulocyte colony-stimulating 
factor (G-CSF) support (Grade AII) [40-43]. Granulocyte concentrate 
transfusion can be considered, especially in pediatric fusariosis 
(Grade CIII) [42, 43]. Antifungal treatment, combined with surgical 
debridement of infected tissues, is recommended in patients with 
hematological malignancies or undergoing HCT (Grade AII) [42, 43].
Therapy of scedosporiosis
The most virulent species of Scedosporium pathogenic for 
immunocompromised patients include Lamentospora aurantiacum 
(formerly Scedosporium prolificans) and S. aurantiacum, both 
predominant in hot countries, and S. apiospermum, predominant in 
areas with moderate temperature [43]. They may cause infection of 
any organ with a preference for the sinopulmonary area, skin, and the 
CNS. Disseminated scedosporiosis manifests with fever and positive 
blood culture in the majority of patients and can be associated with 
skin rash and focal CNS symptoms [41].
Scedosporium spp. belong to the most drug-resistant fungi, and no 
strong recommendation can be provided, especially in the case of L. 
aurantiacum. They demonstrate resistance to polyenes and reduced 
sensitivity to echinocandins; that is why a choice of treatment 
should be optimally driven by susceptibility testing [41]. According 
to EFISG/ESCMID/ECMM joint recommendations, voriconazole is 
the treatment of choice (Grade AII) with surgical debridement of the 
localized lesions (Grade AIII) [43]. Infections with L. aurantiacum 
are difficult to manage, and outcome may be improved by surgical 
excision of lesions, restoration of circulating polymorphonuclear and 
mononuclear leukocytes, and combined therapy with voriconazole 
plus terbinafine or other combination (Tab. XV).
Dosing of antifungals
The pharmacokinetics of antifungal drugs in children can vary from 
those in adults. The recommended dosing of antifungals in adults 
and children is shown in table XVI.
Table XIV. Summarized recommendations for the management of fusariosis [40–43]
Intervention Recommendations Comments
First- line treatment
Voriconazole AII Therapeutic drug monitoring 
LAmB BII Fungi resistance possible
ABLC CIII Limited case reports
Salvage therapy
Posaconazole AII Therapeutic drug monitoring
Voriconazole AIII Therapeutic drug monitoring
Adjunctive treatment
Surgical debridement AII Improve the outcome
Reversal of immunosuppression AII Improve the outcome
Granulocyte transfusion CIII With cautions in HCT patients
Recommendations for adults; can be applied to children;  LAmB – liposomal amphotericin-B; ABLC – amphotericin B lipid complex
Table XV. Summarized recommendations for the management of scedosporiosis [41–43]
Intervention Recommendations Comments
First-line treatment
Voriconazole AII Therapeutic drug monitoring 
LAmB CIII Variable activity
Posaconazole CIII Case reports
Combination therapy*
Posaconazole plus terbinafine BIII Case reports
Voriconazole plus terbinafine BIII Case reports
Voriconazole plus caspofungin BIII Case reports
Adjunctive treatment
Surgical debridement and drainage AIII Essential for favorable outcome
Reversal of immunosuppression AII Improves the outcome
Granulocyte transfusion CIII Granulocytes as a protective factor; lack of solid data
*Disseminated or lung infection with Lamentospora auratiacum; recommendations for adults; can be applied to children; LAmB – liposomal amphotericin-B
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Table XVI. Recommended dosing of antifungals in adults and children
Antifungal drug Dosing in adults Dosing in children Comments
Fluconazole Prophylaxis: 50–400 mg, po/iv, qd
Treatment: loading dose 400–800 mg, iv, qd on Day1, 
then 400 mg, iv, qd
8–12 mg/kg/day, iv/po
Itraconazole Prophylaxis: 200 mg, iv, qd on Day 1, followed by oral 
solution 200 mg
Treatment: 200 mg, iv, qd
It is discouraged to use itraconazole in 
tablets, since bioavailability is poor.
Only tablets are available in Poland – this 
formula is not recommended due to poor 
bioavailability
Posaconazole Prophylaxis: 200 mg tid suspension, or 300 mg tablet 
qd
Treatment: 200 mg qid or 400 mg bid suspension or 
300 mg tablet bid on Day 1, followed by 300 mg qd
600–800 mg/day, po In 2–4 daily doses. For children with bw < 
40 kg, dosing as recommended in table VI
Only suspension formula is reimbursed in 
Poland. Tablets are not available in Poland
Voriconazole Loading dose of 6 mg/kg, iv, bid on Day 1, followed 
by 4 mg/kg, iv, bid.





Detailed dosing data for children and 
adults are shown in table VIII
Isavuconazole Loading doses of 372 mg of isavuconazonium sulfate 
(equivalent to 200 mg of isavuconazole) every 
8 hours for 6 doses (48 hours) via po (2 capsules) 
or iv administration, followed by 372 mg qd, po/iv, 
starting 12–24 hours after the last loading dose




Not licensed for children




Max: 50 mg/day (Day 1: 70 mg)
Micafungin 100–150 mg, iv, qd; no loading dose is required 1–4 mg/kg/day, iv Dosing in prophylaxis: 1 mg/kg/day 
(>50 kg: 50 mg); therapeutic 2 mg/kg/day; 
dosing in infants: 4 mg/kg/day
Liposomal 
amphotericin B (LAmB)
5 mg/kg, iv, qd 3–5 mg/kg/day, iv
Amphotericin B lipid 
complex (ABLC)
3–5 mg/kg, iv, qd 5 mg/kg/day, iv
Amphotericin B 
deoxycholate
0.5–1 mg/kg, qd It is discouraged to use this formulation 
of AmB
Flucytosine 4 × 25 mg/kg bw 4 × 25 mg/kg bw In CNS cryptococcosis, in combination 
therapy with LAmB, for at least 14 days
Terbinafine 1 × 250 mg/day (tablet) Not recommended for children (in SPC)
iv – intravenous; po – per os; d – day (24 hours); bw – body weight; qd – once daily; bid – twice daily; tid – three times daily
71
A c t a  H a e m a t o l o g i c a  P o l o n i c a
 
References
[1] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the 
consensus definitions of invasive fungal disease from the European 
Organization for Research and Treatment of Cancer and the Mycoses 
Study Group Education and Research Consortium. Clin Infect Dis 
2019 [Epub ahead of print].
[2] Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance 
for invasive fungal infections in hematopoietic stem cell transplant 
recipients, 2001-2006: overview of the Transplant-Associated 
Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 
2010;50:1091–100.
[3] Czyzewski K, Styczynski J, Giebel S, et al. Age-dependent 
determinants of infectious complications profile in children and 
adults after hematopoietic cell transplantation: lesson from the 
nationwide study. Ann Hematol 2019;98:2197–211.
[4] Czyzewski K, Galazka P, Fraczkiewicz J, et al. Epidemiology and 
outcome of invasive fungal disease in children after hematopoietic 
cell transplantation or treated for malignancy: Impact of national 
programme of antifungal prophylaxis. Mycoses 2019;62:990–8.
[5] Styczynski J. Infectious complications in children and adults with 
hematological malignancies. Acta Haematol Pol 2019;50:167–73.
[6] Styczyński J. ABC of viral infections in hematology: focus on 
herpesviruses. Acta Haematol Pol 2019;50:159–66.
[7] Dragonetti G, Criscuolo M, Fianchi L, Pagano L. Invasive aspergillosis 
in acute myeloid leukemia: Are we making progress in reducing 
mortality? Med Mycol 2017;55:82–6.
[8] Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 
1990s in a tertiary-care cancer center. Clin Infect Dis 2000;30:851–6.
[9] Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic 
haematopoietic stem cell transplantation: a French Multicentre 
Cohort Study (2003-2008). Clin Microbiol Infect 2012;18:E396–400.
[10] Kowalczyk JR, Stefaniak MJ, Kałwak K, Matysiak M, Szczepański T, 
Styczyński J. Standards of diagnostic and therapeutic management 
of invasive fungal disease in children: recommendations of Polish 
Society of Pediatric Oncology and Hematology. Post Nauk Med 
2016;29:528–33
[11] Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for 
antifungal management in leukemia and hematopoietic stem cell 
transplant recipients: summary of the ECIL 3 – 2009 update. Bone 
Marrow Transplant 2011;46:709–18.
[12] Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the 
treatment of invasive candidiasis, aspergillosis and mucormycosis 
in leukemia and hematopoietic stem cell transplant patients. 
Haematologica 2017;102:433–44.
[13] Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on 
Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, 
and treatment of invasive fungal diseases in paediatric patients with 
cancer or allogeneic haemopoietic stem-cell transplantation. Lancet 
Oncol 2014;15:e327–40.
[14] Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive 
summary: practice guidelines for the diagnosis and management 
of aspergillosis: 2016 update by the Infectious Diseases Society of 
America. Clin Infect Dis 2016;63:433–42.
[15] Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice 
guidelines for the diagnosis and management of Aspergillosis: 2016 
update by the Infectious Diseases Society of America. Clin Infect Dis 
2016;63:e1–60.
[16] Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: 
clinical practice guideline for the management of Candidiasis: 2016 
update by the Infectious Diseases Society of America. Clin Infect Dis 
2016;62:409–17.
[17] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline 
for the management of Candidiasis: 2016 update by the Infectious 
Diseases Society of America. Clin Infect Dis 2016;62:e1–50.
[18] Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and 
management of Aspergillus diseases: executive summary of the 
2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 
Suppl 1:e1–38.
[19] Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive 
fungal infections in immunocompromised patients with cancer and 
hematopoietic stem cell transplants: an international consensus. Clin 
Infect Dis 2002;34:7–14.
[20] De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive 
fungal disease from the European Organization for Research 
and Treatment of Cancer/Invasive Fungal Infections Cooperative 
Group and the National Institute of Allergy and Infectious Diseases 
Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 
2008;46:1813–21.
[21] Welzen ME, Bruggemann RJ, Van Den Berg JM, et al. A twice 
daily posaconazole dosing algorithm for children with chronic 
granulomatous disease. Pediatr Infect Dis J 2011;30:794–7.
[22] Arrieta AC, Sung L, Bradley JS, et al. A non-randomized trial to assess 
the safety, tolerability, and pharmacokinetics of posaconazole oral 
suspension in immunocompromised children with neutropenia. 
PLoS One 2019;14:e0212837.
[23] Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. 
Empirical antifungal therapy for patients with neutropenia and 
persistent fever: systematic review and meta-analysis. Eur J Cancer 
2008;44:2192–203.
[24] Chen K, Wang Q, Pleasants RA, et al. Empiric treatment against 
invasive fungal diseases in febrile neutropenic patients: a systematic 
review and network meta-analysis. BMC Infect Dis 2017;17:159.
[25] Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in 
febrile neutropenic patients treated for hematological malignancies. 
Intern Med 2007;46:3–9.
[26] Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal 
agent, as empirical therapy in acute leukemia patients with febrile 
neutropenia. Intern Med 2006;45:259–64.
[27] Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for 
empirical therapy in patients with persistent fever and neutropenia. 
National Institute of Allergy and Infectious Diseases Mycoses Study 
Group. N Engl J Med 1999;340:764–71.
[28] Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal 
amphotericin B for empirical antifungal therapy in patients with 
persistent fever and neutropenia. N Engl J Med 2004;351:1391–402.
A c t a  H a e m a t o l o g i c a  P o l o n i c a
72
[29] Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with 
liposomal amphotericin B for empirical antifungal therapy in patients 
with neutropenia and persistent fever. N Engl J Med 2002;346: 
225–34.
[30] Powers JH, Dixon CA, Goldberger MJ. Voriconazole versus liposomal 
amphotericin B in patients with neutropenia and persistent fever. 
N Engl J Med 2002;346:289-90.
[31] Fung M, Kim J, Marty FM, Schwarzinger M, Koo S. Meta-analysis 
and cost comparison of empirical versus pre-emptive antifungal 
strategies in hematologic malignancy patients with high-risk febrile 
neutropenia. PLoS One 2015;10:e0140930.
[32] Schwartz IS, Patterson TF. The emerging threat of antifungal resistance 
in transplant infectious diseases. Curr Infect Dis Rep 2018;20:2.
[33] Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez 
de Pipaon M, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on 
hospital mortality of catheter removal and adequate antifungal 
therapy in Candida spp. bloodstream infections. J Antimicrob 
Chemother 2013;68:206–13.
[34] Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy 
on outcomes in patients with candidemia and other forms of invasive 
candidiasis: a patient-level quantitative review of randomized trials. 
Clin Infect Dis 2012;54:1110–22.
[35] Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus 
voriconazole for primary treatment of invasive mould disease 
caused by Aspergillus and other filamentous fungi (SECURE): 
a phase 3, randomised-controlled, non-inferiority trial. Lancet 
2016;387:760–9.
[36] Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment 
of mucormycosis in patients with hematological malignancies: 
guidelines from the 3rd European Conference on Infections in 
Leukemia (ECIL 3). Haematologica 2013;98:492–504.
[37] Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 
230 cases accrued by the registry of the European Confederation of 
Medical Mycology (ECMM) Working Group on Zygomycosis between 
2005 and 2007. Clin Microbiol Infect 2011;17:1859–67.
[38] Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole 
treatment for mucormycosis: a single-arm open-label trial and 
case-control analysis. Lancet Infect Dis 2016;16:828–37.
[39] Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North 
Am 2016;30:143–63.
[40] Al-Hatmi AMS, Bonifaz A, Ranque S, Sybren de Hoog G, Verweij PE, 
Meis JF. Current antifungal treatment of fusariosis. Int J Antimicrob 
Agents 2018;51:326–32.
[41] Blyth CC, Gilroy NM, Guy SD, et al. Consensus guidelines for the 
treatment of invasive mould infections in haematological malignancy 
and haemopoietic stem cell transplantation, 2014. Intern Med J 
2014;44:1333–49.
[42] McCarthy MW, Katragkou A, Iosifidis E, Roilides E, Walsh TJ. Recent 
advances in the treatment of Scedosporiosis and Fusariosis. J Fungi 
(Basel) 2018;4:73.
[43] Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint 
guidelines on diagnosis and management of hyalohyphomycosis: 
Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 
2014;20(Suppl 3):27–46.
